Niraparib Dosing for Primary and Metastatic Brain Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for effective therapies to treat primary and metastatic brain cancer, which has a low 5-year survival rate and high mortality rates, with existing treatments being inadequate.
Innovation Solution
Administering an effective dose of niraparib or its pharmaceutically acceptable salt to treat primary or metastatic brain cancer, potentially combined with radiation therapy and maintenance treatment, to achieve sufficient tumor concentrations of niraparib beyond a 5-fold of its biochemical IC50 value.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatments are used for brain cancer, then treatment is provided, but treatment efficacy is insufficient and survival rate remains low
Solution Approach 1:
The patent achieves effective brain cancer treatment by changing the concentration parameter of niraparib through multiple dosing regimens (e.g., 300 mg daily for 14 days followed by 200 mg daily for 14 days) to achieve tumor concentrations exceeding 5-fold of the biochemical IC50 value, thereby resolving the contradiction between treatment efficacy and survival rate improvement
2Reliability
If niraparib is administered to achieve therapeutic concentrations, then treatment efficacy is enhanced, but treatment complexity increases
Solution Approach 1:
The patent applies preliminary action by administering niraparib in a specific dosing schedule (300 mg daily for 14 days followed by 200 mg daily for 14 days) before evaluating response, ensuring therapeutic concentrations are achieved and maintained. This predetermined regimen simplifies the overall treatment complexity while ensuring efficacy
3Productivity
If combination therapy with radiation is used, then survival is extended, but treatment side effects increase
Solution Approach 1:
The patent uses niraparib as an intermediary agent that enhances the effectiveness of radiation therapy while potentially reducing the required radiation dose. By administering niraparib in a specific dosing regimen that achieves therapeutic concentrations, the treatment extends survival while the intermediary作用 helps mitigate the harmful effects of intensive combination therapy
Data Source
AI summary
The present invention provides methods of administering niraparib for the treatment of primary and metastatic brain cancer.